UroGen Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell UroGen Pharma and other ETFs, options, and stocks.

About URGN

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. 

CEO
Elizabeth Barrett
CEOElizabeth Barrett
Employees
291
Employees291
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
2004
Founded2004
Employees
291
Employees291

URGN Key Statistics

Market cap
2.39B
Market cap2.39B
Price-Earnings ratio
-24.65
Price-Earnings ratio-24.65
Dividend yield
Dividend yield
Average volume
1.13M
Average volume1.13M
High today
$49.56
High today$49.56
Low today
$48.41
Low today$48.41
Open price
$48.92
Open price$48.92
Volume
793.24K
Volume793.24K
52 Week high
$49.67
52 Week high$49.67
52 Week low
$15.86
52 Week low$15.86

Stock Snapshot

As of today, UroGen Pharma(URGN) shares are valued at $48.92. The company's market cap stands at 2.39B, with a P/E ratio of -24.65.

As of 2026-08-18, UroGen Pharma(URGN) stock has fluctuated between $48.41 and $49.56. The current price stands at $48.92, placing the stock +1.1% above today's low and -1.3% off the high.

UroGen Pharma(URGN) shares are trading with a volume of 793.24K, against a daily average of 1.13M.

During the past year, UroGen Pharma(URGN) stock moved between $15.86 at its lowest and $49.67 at its peak.

During the past year, UroGen Pharma(URGN) stock moved between $15.86 at its lowest and $49.67 at its peak.

URGN News

Simply Wall St 4d
Is UroGen Pharma Overvalued As Sales Growth And Patent Clarity Lift Confidence?

UroGen Pharma (URGN) is back in focus after its second quarter 2026 earnings, which showed significantly higher sales, a smaller net loss, and key updates on ZU...

Is UroGen Pharma Overvalued As Sales Growth And Patent Clarity Lift Confidence?

Analyst ratings

88%

of 8 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

People also own

Based on the portfolios of people who own URGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.